Synbias Co-Owns Cancer Drug IP, Can't Be Sued, Judge Rules

Law360, New York (September 6, 2013, 8:52 PM EDT) -- In an unusual case that required an interpretation of Ukrainian patent law to determine ownership of U.S. patents, a California federal judge has ruled that Synbias Pharma cannot be sued by Solux Corp. for infringing chemotherapy drug patents because Synbias co-owns them.

In the Aug. 30 decision, U.S. District Judge Marilyn Huff said that Solux, which is listed as a co-owners of the patents, lacks standing to sue Synbias for infringement because the patents were never properly transferred to Solux.

"In sum, Synbias was at least...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.